| |
| |
| Exchange: |
Nasdaq Small Cap |
| Security
Type: |
Common |
| Shares
Out: |
173,744,000 |
| Market
Cap: |
1.07(B) |
| Last
Volume: |
148,509 |
Avg
Vol: |
0 |
| 52
Week Range: |
$5.58 - $15.45 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Health Services |
| Level
III Sector: |
Medical Laboratories & Research |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 8.3 |
| Insider 3/6 Months : 8.9 |
|
| Guru Rank Number : 607 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Ironwood Pharmaceuticals is a gastrointestinal (GI) healthcare company focusing on developing the treatment of GI diseases. LINZESS® (linaclotide), Co.'s commercial product, is a product in a class of GI medicines called guanylate cyclase type C agonists and is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). LINZESS is available to adult men and women suffering from IBS-C or CIC in the U.S. and Mexico and to adult men and women suffering from IBS-C in Japan and China. Co. has partnerships with pharmaceutical companies to support the development and commercialization of linaclotide.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
17,604 |
53,676 |
53,676 |
| Total Buy Value |
$0 |
$160,420 |
$460,539 |
$460,539 |
| Total People Bought |
0 |
2 |
2 |
2 |
| Total Buy Transactions |
0 |
2 |
3 |
3 |
| Total Shares Sold |
226,641 |
507,557 |
529,791 |
1,205,966 |
| Total Sell Value |
$1,459,885 |
$5,741,044 |
$5,974,538 |
$13,645,593 |
| Total People Sold |
6 |
7 |
8 |
11 |
| Total Sell Transactions |
7 |
12 |
16 |
50 |
| End Date |
2024-03-28 |
2023-12-26 |
2023-06-27 |
2022-06-27 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Mcguire Terrance |
Director |
– • – |
2016-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
239 |
20,217 |
|
- |
|
| Walsh Christopher T Phd |
Director |
– • – |
2016-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
239 |
47,160 |
|
- |
|
| Hecht Peter M |
Chief Executive Officer |
• • – |
2016-03-11 |
4 |
AS |
$10.66 |
$426,400 |
D/D |
(40,000) |
4,670,322 |
|
- |
|
| Hecht Peter M |
Chief Executive Officer |
• • – |
2016-03-11 |
4 |
OE |
$1.56 |
$62,400 |
D/D |
40,000 |
4,710,322 |
|
- |
|
| Hecht Peter M |
Chief Executive Officer |
• • – |
2016-03-10 |
4 |
AS |
$10.63 |
$425,200 |
D/D |
(40,000) |
4,670,322 |
|
- |
|
| Hecht Peter M |
Chief Executive Officer |
• • – |
2016-03-10 |
4 |
OE |
$1.56 |
$62,400 |
D/D |
40,000 |
4,710,322 |
|
- |
|
| Hecht Peter M |
Chief Executive Officer |
• • – |
2016-03-09 |
4 |
AS |
$10.87 |
$434,800 |
D/D |
(40,000) |
4,670,322 |
|
- |
|
| Hecht Peter M |
Chief Executive Officer |
• • – |
2016-03-09 |
4 |
OE |
$1.56 |
$344,432 |
D/D |
220,790 |
4,710,322 |
|
- |
|
| Currie Mark G |
Chief Scientific Officer |
• – – |
2016-03-09 |
4 |
OE |
$1.56 |
$251,001 |
D/D |
160,898 |
385,000 |
|
- |
|
| Currie Mark G |
Chief Scientific Officer |
• – – |
2016-03-09 |
4 |
AS |
$10.86 |
$1,629,000 |
D/D |
(150,000) |
374,102 |
|
- |
|
| Olanoff Lawrence S |
Director |
– • – |
2016-03-07 |
4 |
AS |
$11.11 |
$24,442 |
D/D |
(2,200) |
11,031 |
|
- |
|
| Consylman Gina |
Chief Accounting Officer |
• – – |
2016-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
21,330 |
|
- |
|
| Gilbert Halley E |
Chief Legal Officer |
• – – |
2016-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
32,500 |
68,947 |
|
- |
|
| Graney Thomas |
Chief Financial Officer |
• – – |
2016-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
17,500 |
22,637 |
|
- |
|
| Consylman Gina |
Chief Accounting Officer |
• – – |
2016-02-24 |
4 |
AS |
$8.50 |
$3,570 |
D/D |
(420) |
6,330 |
|
- |
|
| Mccourt Thomas A |
Chief Commercial Officer |
• – – |
2016-02-24 |
4 |
AS |
$8.50 |
$13,600 |
D/D |
(1,600) |
27,312 |
|
- |
|
| Currie Mark G |
Chief Scientific Officer |
• – – |
2016-02-24 |
4 |
AS |
$8.50 |
$1,297,809 |
D/D |
(152,154) |
374,102 |
|
- |
|
| Currie Mark G |
Chief Scientific Officer |
• – – |
2016-02-24 |
4 |
OE |
$1.56 |
$234,000 |
D/D |
150,000 |
524,102 |
|
- |
|
| Graney Thomas |
Chief Financial Officer |
• – – |
2016-02-24 |
4 |
AS |
$8.50 |
$4,786 |
D/D |
(563) |
5,137 |
|
- |
|
| Gilbert Halley E |
Chief Legal Officer |
• – – |
2016-02-24 |
4 |
AS |
$8.50 |
$23,613 |
D/D |
(2,778) |
36,447 |
|
- |
|
| Owens Edward P |
Director |
– • – |
2016-02-24 |
4 |
B |
$8.32 |
$83,200 |
D/D |
10,000 |
144,006 |
2.39 |
- |
|
| Currie Mark G |
Chief Scientific Officer |
• – – |
2016-01-04 |
4 |
OE |
$1.56 |
$99,999 |
D/D |
64,102 |
374,102 |
|
- |
|
| Walsh Christopher T Phd |
Director |
– • – |
2015-12-15 |
4 |
A |
$0.00 |
$0 |
D/D |
227 |
46,921 |
|
- |
|
| Mcguire Terrance |
Director |
– • – |
2015-12-15 |
4 |
A |
$0.00 |
$0 |
D/D |
227 |
19,978 |
|
- |
|
| Hecht Peter M |
Chief Executive Officer |
• • – |
2015-12-15 |
4 |
S |
$11.07 |
$812,737 |
D/D |
(73,418) |
0 |
|
- |
|
931 Records found
|
|
Page 20 of 38 |
|
|
0.15 (2.37%) 
